Chronic Pain - Market Insight, Epidemiology, and Market Forecast - 2036

Chronic Pain Insights and Trends

• According to analysis, the chronic pain market across the 7MM was valued at approximately USD 12 billion in 2025 and is projected to expand at a Compounded Annual Growth Rate (CAGR) of 5.1 %, reflecting steady growth driven by the anticipated entry of advanced therapies and improved clinical management.
• According to estimates, the chronic pain pipeline is moderately diversified, with investigational therapies targeting the key indications included in this analysis, namely chronic back pain/chronic lower back pain (CLBP), osteoarthritis, migraine, rheumatoid arthritis-associated pain, fibromyalgia, and neuropathic pain.
• In 2025, the United States accounted for approximately 44 million diagnosed prevalent cases of Chronic Pain.
• The growing prevalence of chronic pain among older adults reflects the cumulative impact of lifelong infections, chronic inflammation, impaired mucociliary clearance, and age-related comorbidities. This trend positions chronic pain as an increasingly important contributor to respiratory morbidity within aging populations.
• The marketed treatment landscape for chronic pain includes EXILBY, NUCYNTA ER, BELBUCA, and XTAMPZA ER for chronic back pain; ZILRETTA and JOYCLU for osteoarthritis; EMGALITY, VYEPTI, AIMOVIG, AJOVY, BOTOX, and QULIPTA/AQUIPTA for migraine; TONMYA for fibromyalgia; and TARLIGE, QUTENZA, and HORIZANT for neuropathic pain, among others.
• Overall, the chronic pain market is evolving toward increasingly indication-specific competition rather than a single broad treatment market.
• The emerging late-stage assets include abobotulinumtoxinA (DYSPORT), XEOMIN, and rimegepant (NURTEC) for migraine; TLC599, Lorecivivint, MOTYS, and Orforglipron for osteoarthritis; suzetrigine (JOURNAVX) for painful diabetic peripheral neuropathy; AXS-14 (esreboxetine) for fibromyalgia; and Vicatertide (SB-01), Rexlemestrocel-L, SP-102 (SEMDEXA), and VER-01 (EXILBY) for CLBP, among others.
• Chronic back pain remains a major contributor to the overall chronic pain burden, particularly in aging markets such as Japan, where its patient population is projected to increase through 2036. The continued expansion of musculoskeletal pain therefore represents an important shift in the composition of the chronic pain population.

Chronic Pain Market size and forecast

• 2025 Chronic Pain Market Size in the 7MM: USD 12 billion
• Chronic Pain Growth Rate (2026-2036) in the 7MM: 5.1% CAGR

The ‘Chronic Pain - Market Insights, Epidemiology and Market Forecast - 2036’ report delivers an in-depth understanding of chronic pain, historical and forecasted epidemiology, as well as the chronic pain market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The chronic pain market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, chronic pain patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in chronic pain and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Geography Covered

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Chronic Pain Understanding and Treatment Algorithm

Chronic Pain Overview and Diagnosis

Chronic pain is persistent or recurrent pain that typically lasts for more than three months or beyond the expected period of tissue healing. It can arise from a wide range of underlying conditions, including musculoskeletal disorders, neuropathic conditions, inflammatory diseases, cancer, and other chronic illnesses. The condition is often associated with physical limitations, sleep disturbances, emotional distress, and reduced quality of life, with its impact frequently compounded by aging and the presence of multiple comorbidities.

Chronic pain is primarily diagnosed through a comprehensive clinical assessment that includes a detailed medical history, physical examination, and evaluation of pain characteristics, including its location, intensity, duration, and impact on daily functioning. Validated pain assessment tools may be used to quantify pain severity and monitor its progression. Additional diagnostic tests, such as imaging studies, laboratory investigations, nerve conduction studies, or other specialized assessments, may be performed depending on the suspected underlying cause. The diagnostic approach aims to identify potential pain generators and contributing conditions while assessing the overall impact of chronic pain on physical function and quality of life.

Chronic Pain Treatment Landscape

Chronic pain treatment involves both pharmacological and non-pharmacological interventions, with the goal of reducing pain, improving physical function, and enhancing the quality of life of affected individuals. The treatment approach is highly individualized and depends on the underlying cause, type, severity, and duration of pain, as well as functional impairment, comorbidities, and patient-specific needs. Pharmacological options may include non-opioid analgesics, nonsteroidal anti-inflammatory drugs, antidepressants, anticonvulsants, and other targeted therapies, depending on the type and underlying cause of pain. In selected patients, interventional procedures or other specialized approaches may also be considered.

Non-pharmacological interventions, including physical therapy, exercise, psychological therapies, and multidisciplinary rehabilitation, play an important role in improving function and overall well-being. However, despite the availability of multiple therapeutic approaches, many patients continue to experience persistent or recurrent pain, functional limitations, and a substantial impact on daily activities and quality of life.

Chronic Pain Unmet Needs

The section “unmet needs of Chronic Pain” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Heterogeneous disease biology and absence of predictive biomarkers limit precision treatment.
• Persistent reliance on symptomatic analgesia limits long-term disease management.
• High unmet need for durable, long-acting therapies continues to drive repeat treatment burden.
• Heterogeneous epidemiological evidence limits accurate market sizing across chronic pain indications.
• Fragmented multidisciplinary care delays appropriate patient identification and advanced treatment utilization.

Chronic Pain Epidemiology

Key Findings from Chronic Pain Epidemiological Analysis and Forecast

• In the US, there were approximately 62 million prevalent cases of chronic pain in 2025, indicating a substantial patient population and growing demand for long-term pain management therapies.
• In EU4 and the UK, moderate chronic pain accounted for the highest number of cases in 2025, with approximately 26 million cases, followed by severe (~14 million) and mild (~12 million) cases.
• In EU4 and the UK, females accounted for the highest number of diagnosed prevalent cases of chronic pain in 2025, with approximately 31 million cases, compared with ~21 million cases among males.
• In Japan, the 65 years and older age group accounted for the highest number of prevalent chronic pain cases in 2025, with approximately 6 million cases, followed by the 45-64 years (~5 million), 30-44 years (~3 million), and 18-29 years (~2 million) age groups.
• In Japan, chronic back pain accounted for the highest number of prevalent chronic pain cases in 2025, with approximately 10 million cases, followed by osteoarthritis (~7 million), rheumatoid arthritis (~3 million), fibromyalgia and neuropathic pain (~2 million each), and migraine (~2 million). This distribution highlights the substantial contribution of musculoskeletal conditions to the chronic pain burden.

Chronic Pain Drug Analysis & Competitive Landscape

The Chronic Pain drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across mid and late Phase clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the chronic pain treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Chronic Pain therapeutics market.

Approved Therapies for Chronic Pain

Atogepant (AQUIPTA,QULIPTA): AbbVie

Atogepant is approved for migraine prophylaxis in more than 60 countries and is marketed as AQUIPTA in EU and QULIPTA in the US, Canada, Israel, and Puerto Rico. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide, which is thought to play a causal role in migraine.

• In April 2026, AbbVie presented results from a completed Phase III study which assessed atogepant with onabotulinumtoxinA at the American Academy of Neurology (AAN).
• In February 2026, AbbVie reported that it has received marketing approval in Japan for atogepant for the prevention of migraine attacks in adult patients.
• In August 2023, it was approved as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month on the basis of two trials PROGRESS and ADVANCE.

Chronic Pain Pipeline Analysis

SL1002: Saol Therapeutics

SL-1002 is a novel injectable chemoneurolytic agent being developed specifically for chronic knee pain associated with osteoarthritis. It is designed as a single-treatment approach for persistent osteoarthritis-related knee pain, with Phase II evaluation completed and a Phase III study currently underway in patients with mild-to-moderate knee osteoarthritis.

• In April 2025, SL-1002 advanced toward Phase III development, followed by the initiation of a Phase III trial in November 2025 for chronic knee pain associated with mild-to-moderate osteoarthritis.
• In September 2023, Saol Therapeutics completed enrollment in the Phase II COMPASS trial, evaluating SL-1002 for chronic knee pain associated with osteoarthritis, with 132 patients enrolled.

Chronic Pain Key Players, Market Leaders and Emerging Companies

• Novo Nordisk
• Insmed
• Saol Therapeutics
• Ipsen

Chronic Pain Drug Updates

• In July 2026, Ipsen reported positive Phase III BEOND topline results for AbobotulinumtoxinA (DYSPORT), demonstrating a significant reduction in monthly migraine days and supporting its potential for migraine prevention.
• In June 2026, Eli Lilly and Company reported additional positive Phase III TRIUMPH-1 results for retatrutide, demonstrating substantial weight loss and meaningful improvements in knee osteoarthritis pain, with findings presented at the American Diabetes Association 86th Scientific Sessions.
• In April 2026, Novo Nordisk initiated two Phase III trials, AMAZE 5 and AMAZE 6, evaluating once-weekly zenagamtide in adults with overweight/obesity and knee osteoarthritis, with completion anticipated in August 2028.
• In April 2025, SL-1002 advanced toward Phase III development, with a Phase III trial initiated in November for chronic knee pain associated with mild-to-moderate osteoarthritis.

Chronic Pain Market Outlook

The chronic pain market is expected to grow steadily, driven by a rising patient population, increasing disease awareness, improved diagnosis, and significant unmet need for effective long-term therapies. The emergence of novel targeted and personalized treatments is expected to further evolve the treatment landscape, improve patient outcomes, and support growth in the 7MM chronic pain market from 2026-2036, creating strong commercial potential for marketed and pipeline therapies.

• In 2025, the US chronic pain market was valued at approximately USD 8 billion and is projected to grow steadily through 2036, driven by the anticipated uptake of novel therapies, persistent unmet needs, and demand for more effective and durable pain relief.
• The EU4 and the UK chronic pain market was valued at approximately USD 3 billion in 2025, driven by the substantial burden of chronic musculoskeletal and neuropathic pain. Germany generated the highest revenue, accounting for more than USD 900 million in 2025.
• Delayed diagnosis of chronic pain conditions and fragmented, trial-and-error treatment approaches are expected to remain key market constraints, as prolonged reliance on NSAIDs, opioids, antidepressants, and anticonvulsants may delay adoption of newer targeted therapies and limit overall market growth.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Pain (2022-2036 Forecast)

The treatment landscape of chronic pain is rapidly evolving, with a diverse pipeline spanning non-opioid analgesics, biologics, regenerative therapies, neuromodulatory approaches, and other mechanism-specific treatments, collectively aiming to provide more effective, durable, and targeted pain relief beyond conventional symptomatic therapies.

• Novel Non-Opioid and Targeted Therapies: This approach focuses on targeting specific pain pathways and underlying mechanisms involved in chronic pain. Emerging therapies, including non-opioid analgesics, biologics, regenerative therapies, and neuromodulatory approaches, are being developed to provide more effective and durable pain relief while potentially reducing the limitations associated with conventional analgesic therapies.

Chronic Pain Drug Uptake

This section focuses on the uptake of potential therapies expected to launch in the chronic pain market during the forecast period (2026-2036). The analysis covers the uptake and peak performance of emerging therapies, key factors influencing their adoption during the prime growth years, patient uptake by therapy, and anticipated sales generated by each asset.

The chronic pain pipeline includes several novel and targeted therapies being developed across chronic back pain, osteoarthritis, migraine, fibromyalgia, and neuropathic pain. These therapies are expected to address key unmet needs such as inadequate pain control, functional limitations, tolerability concerns, and the need for durable treatment options.

• Following its anticipated US launch, abobotulinumtoxinA (DYSPORT) is expected to demonstrate moderate market uptake, supported by its established clinical profile, familiarity among healthcare providers, and potential to address the unmet need for effective preventive treatment options in migraine.

Market Access and Reimbursement of Approved therapies in Chronic Pain

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

United State

The US health care system includes both private and public health insurance coverage. Whether a drug product is covered, and at what price, is determined by each payer’s coverage, coding, and payment criteria for health insurance plans. The largest government-funded programs are Medicare and Medicaid. Private plans, which cover far more Americans than public plans, have more flexibility to make coverage and reimbursement determinations.

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

• In the United States, ZILRETTA offers patient access support through a co-pay program for eligible commercially insured patients, while Medicare Part B generally covers 80% of the Medicare-approved amount when medically necessary and administered by a healthcare professional.

Chronic Pain Therapies Price Scenario & Trends

Pricing and analogue assessment of chronic pain therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Chronic Pain

To keep up with chronic pain market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the chronic pain emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

The analysts engaged with 25+ key opinion leaders (KOLs) across major markets to capture country-level insights in chronic pain Leading centers such as Harvard University, Brigham and Women's Hospital, Friedrich Schiller University Jena, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate current and emerging chronic pain, therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in chronic pain.

Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of chronic pain, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of chronic pain, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the chronic pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM chronic pain market.

Report Insights

• Chronic Pain Patient Population Forecast
• Chronic Pain Therapeutics Market Size
• Chronic Pain Pipeline Analysis
• Chronic Pain Market Size and Trends
• Chronic Pain Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑Based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Chronic Pain Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Pain Treatment Addressable Market (TAM)

Chronic Pain Competitive Landscape

• Chronic Pain Major Companies Insights
• Chronic Pain Price trends and Analogue Assessment
• Chronic Pain Therapies Drug Adoption/Uptake
• Chronic Pain Therapies Peak Patient Share analysis

Report Assessment

• Chronic Pain Current Treatment Practices
• Chronic Pain Unmet Needs
• Chronic Pain Clinical Development Analysis
• Chronic Pain Emerging Drugs Product Profiles
• Chronic Pain Market Attractiveness
• Chronic Pain Qualitative Analysis (SWOT and Attribute analysis)

FAQs

Market Insights

• What was the chronic pain market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of chronic pain?
• What are the disease risks, burdens, and unmet needs of chronic pain? What will be the growth opportunities across the 7MM concerning the patient population with chronic pain?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of chronic pain?
• What are the current guidelines for treating chronic pain in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic pain market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.